Literature DB >> 15012615

Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population.

Svetlana Trofimov1, I Pantsulaia, Ia Pantsulaia, Eugene Kobyliansky, Gregory Livshits.   

Abstract

OBJECTIVES: To determine the ranges of variation of circulating receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG)/macrophage-colony stimulating factor(M-CSF) and to ascertain their potential relationships with age, sex and menopausal status in women, and with sex hormones in a population-based healthy cohort. SUBJECTS AND METHODS: Blood samples were collected with EDTA after an overnight fast. The plasma levels of each of the above biochemical indices were measured by ELISA in a total of 566 apparently healthy individuals aged 18-75 years.
RESULTS: The plasma concentrations of cytokine molecules in the entire sample ranged from 674 to 4929 pg/ml for OPG, from 105 to 4468 pg/ml for soluble RANKL (sRANKL), and from 187 to 7604 pg/ml for M-CSF. The OPG levels demonstrated a clear positive correlation with age in both sexes (r=0.42 and 0.43, P<0.001, for men and women respectively). Application of the two-interval mathematical model revealed that in females OPG levels were age-independent until age 42, but then showed clear and significant correlation with age (r=0.48, P<0.001). As a result, young females (before 42 years) had a substantially lower average OPG level, 1377.8+/-327.68 pg/ml, in comparison with older women, 1666.02+/-397.14 pg/ml. The M-CSF correlation with age was significantly greater in women (r=0.29, P<0.001) compared with men (r=0.17, P<0.01). Significant negative correlations between plasma levels of both OPG and M-CSF with estradiol concentrations were observed in women (r=-0.39, P<0.01; r=-0.25, P<0.001 respectively). sRANKL did not correlate with either age or sex hormones in either women or men.
CONCLUSION: Age and sex affect differently the interindividual variation of OPG, RANKL and M-CSF. Our observations could form the basis for further research to establish provisional reference limits for OPG and RANKL, which are potential markers for benign and malignant processes in bone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15012615     DOI: 10.1530/eje.0.1500305

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  16 in total

1.  Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading.

Authors:  Lidan You; Sara Temiyasathit; Peling Lee; Chi Hyun Kim; Padmaja Tummala; Wei Yao; Wade Kingery; Amanda M Malone; Ronald Y Kwon; Christopher R Jacobs
Journal:  Bone       Date:  2007-09-26       Impact factor: 4.398

2.  A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma.

Authors:  S Ermakov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2011-11-05       Impact factor: 4.507

3.  Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.

Authors:  Nicholas G Angelopoulos; Anastasia Goula; Eugenia Katounda; Grigorios Rombopoulos; Victoria Kaltzidou; Dimitrios Kaltsas; Sophia Malaktari; Vassilis Athanasiou; George Tolis
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

4.  Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis.

Authors:  Abdou S Ellabban; Shereen Refaat Kamel; Shimaa S Ahmed; Ashraf M Osman
Journal:  Rheumatol Int       Date:  2011-02-17       Impact factor: 2.631

5.  Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.

Authors:  Jeffrey R Marks; Karen S Anderson; Paul Engstrom; Andrew K Godwin; Laura J Esserman; Gary Longton; Edwin S Iversen; Anu Mathew; Christos Patriotis; Margaret S Pepe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-03       Impact factor: 4.254

6.  Serum markers of bone turnover in dialyzed patients separated according to age.

Authors:  Alicja E Grzegorzewska; Monika Młot
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 7.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

8.  Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.

Authors:  H Uemura; T Yasui; Y Miyatani; M Yamada; M Hiyoshi; K Arisawa; M Irahara
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

9.  The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

Authors:  Anna Stern; Gail A Laughlin; Jaclyn Bergstrom; Elizabeth Barrett-Connor
Journal:  Eur J Endocrinol       Date:  2007-05       Impact factor: 6.664

Review 10.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.